Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Suchergebnisse

First Mid Bancshares (FMBH) Could Be a Great Choice
First Mid Bancshares (FMBH) Could Be a Great Choice

All investors love getting big returns from their portfolio, whether it's through stocks, bonds, ETFs, or other types of securities. But when you're an income investor, your primary focus is

Can Pilbara Facility Anchor Rio Tinto's Short-Term Growth Trajectory?
Can Pilbara Facility Anchor Rio Tinto's Short-Term Growth Trajectory?

Rio Tinto Group RIO delivered a steady iron ore performance in 2025, driven by strong operational execution across its Pilbara assets. Pilbara iron ore shipments totaled 326.2 million tons for the

CTSH or WIT: Which Is the Better Value Stock Right Now?
CTSH or WIT: Which Is the Better Value Stock Right Now?

Investors interested in Computers - IT Services stocks are likely familiar with Cognizant (CTSH) and Wipro Limited (WIT). But which of these two stocks offers value investors a better bang for their

Government Contracts and Robust Liquidity Fuel Maximus' Growth
Government Contracts and Robust Liquidity Fuel Maximus' Growth

Maximus MMS is benefiting from its reputation as a trusted partner to governments worldwide, delivering cost-effective, scalable solutions in health and human services. Strong shareholder-friendly

Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?
Editas (EDIT) Up 3.8% Since Last Earnings Report: Can It Continue?

A month has gone by since the last earnings report for Editas Medicine (EDIT). Shares have added about 3.8% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue

Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now

Cardinal Health CAH is well positioned for continued growth, thanks to the expansion of its speciality portfolio. The firm delivered strong fiscal second-quarter results, fueled by robust demand in

GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL Partners With Epic to Broaden Galleri Test Access Across US

GRAIL, Inc. GRAL recently announced a strategic collaboration with Epic to integrate its Galleri multi-cancer early detection (MCED) test into one of the most widely used electronic health record

How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results

Pfizer PFE is one of the largest and most successful drugmakers in oncology with an established presence in breast, genitourinary, thoracic, gastrointestinal cancer and blood cancers. It boasts a

Can Reddit's International Expansion Drive More Upside in the Stock?
Can Reddit's International Expansion Drive More Upside in the Stock?

Reddit RDDT is benefiting from its focus on international expansion, which has emerged as a major growth driver for the company. In 2025, the company reported 76% year-over-year growth in

NetApp & Nutanix Partner to Advance Hybrid Cloud & Virtualization
NetApp & Nutanix Partner to Advance Hybrid Cloud & Virtualization

NetApp, Inc. NTAP has announced a collaboration with Nutanix to integrate its Intelligent Data Infrastructure with the Nutanix Cloud Platform (NCP), advancing enterprise virtualization and hybrid

Apple’s Silent Partner Just Validated the Hardware Boom
Apple’s Silent Partner Just Validated the Hardware Boom

With the market swirling with speculation about the future of artificial intelligence (AI), it can be difficult to separate hype from reality.

While many investors focus on the lofty promises of

What Makes Electronic Arts (EA) a New Buy Stock
What Makes Electronic Arts (EA) a New Buy Stock

Investors might want to bet on Electronic Arts (EA), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

All You Need to Know About Lineage, Inc. (LINE) Rating Upgrade to Buy
All You Need to Know About Lineage, Inc. (LINE) Rating Upgrade to Buy

Investors might want to bet on Lineage, Inc. (LINE), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of

All You Need to Know About Getty Realty (GTY) Rating Upgrade to Buy
All You Need to Know About Getty Realty (GTY) Rating Upgrade to Buy

Getty Realty (GTY) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates --

Corning (GLW) Upgraded to Buy: Here's What You Should Know
Corning (GLW) Upgraded to Buy: Here's What You Should Know

Investors might want to bet on Corning (GLW), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the

OverseaChinese Banking (OVCHY) Upgraded to Buy: Here's What You Should Know
OverseaChinese Banking (OVCHY) Upgraded to Buy: Here's What You Should Know

Oversea-Chinese Banking Corporation Limited (OVCHY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most

What Makes Axis Capital (AXS) a New Buy Stock
What Makes Axis Capital (AXS) a New Buy Stock

Axis Capital (AXS) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates --

All You Need to Know About Globus Medical (GMED) Rating Upgrade to Strong Buy
All You Need to Know About Globus Medical (GMED) Rating Upgrade to Strong Buy

Globus Medical (GMED) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting

AngioDynamics (ANGO) Upgraded to Buy: Here's Why
AngioDynamics (ANGO) Upgraded to Buy: Here's Why

AngioDynamics (ANGO) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of

Delta Air Lines Q1 Earnings & Revenues Top Estimates, Up Y/Y
Delta Air Lines Q1 Earnings & Revenues Top Estimates, Up Y/Y

Delta Air Lines (DAL) reported first-quarter 2026 earnings (excluding $1.08 from non-recurring items) of 64 cents per share, which beat the Zacks Consensus Estimate of 61 cents. Earnings increased